Some good news this morning. A new personalised neoantigen vaccine against melanoma is starting its final phase 3 trial at University College Hospital, London. The mRNA vaccine is custom-built for each patient and tells their body to hunt down cancer cells to prevent the disease ever coming back. #Cancer#Melanoma#UCLH#Medicine#Vaccines
